2024-06-09 06:20:00 ET
Cathie Wood is known for two things: picking out innovators that will go on to score a win over the long run, and getting in on these stocks at a great price. The founder and chief executive officer of Ark Invest doesn't mind going against the crowd and choosing companies that have fallen out of favor with other investors. She sees the long-term potential, and this could pay off greatly over time.
One of Wood's favorite technologies in the healthcare space is gene editing, and she's invested in two very promising players in that space. In fact, she added to positions in those companies over the past several days. I'm talking about CRISPR Therapeutics (NASDAQ: CRSP) and Intellia Therapeutics (NASDAQ: NTLA) , two companies using the CRISPR gene-editing technique -- this involves cutting DNA at a particular location and allowing a natural repair process to take over.
This is a game-changing technology because it could produce functional cures for various diseases -- and this may generate explosive growth for companies that sell these products. Let's find out more about these two Cathie Wood favorites.
For further details see:
Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought